Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

- PMLiVE

IFPMA issues psoriasis call to action

Pharma industry body plans to raise awareness of disease

- PMLiVE

Amgen and AZ’s psoriasis antibody clears phase III trial

Brodalumab meets its targets in the AMAGINE-1 study

- PMLiVE

Pfizer set to file Xeljanz for psoriasis

Set to add another indication after positive study results

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

Almirall expands in US via $400m deal to buy Aqua

Will boost its standing in dermatology

- PMLiVE

Psoriasis care falling short says Janssen survey

Claims dermatologists in UK are failing to refer to recommended clinical guidelines

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Baxter taps Coherus for Enbrel biosimilar

Deal to develop copy of Amgen and Pfizer's arthritis and psoriasis is worth up to $246m

- PMLiVE

Forest and Almirall delay FDA filing of COPD drug

Puts companies behind in LAMA/ LABA combination race

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links